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Although membrane proteins represent most therapeutically relevant drug targets, the availability of atomic resolution structures
for this class of proteins has been limited. Structural characterization has been hampered by the biophysical nature of these polytopic
transporters, receptors, and channels, and recent innovations to in vitro techniques aim tomitigate these challenges. One such class
of membrane proteins, the ATP-binding cassette (ABC) superfamily, are broadly expressed throughout the human body, required
for normal physiology and disease-causing when mutated, yet lacks sufficient structural representation in the Protein Data Bank.
However, recent improvements to biophysical techniques (e.g., cryo-electron microscopy) have allowed for previously “hard-to-
study” ABC proteins to be characterized at high resolution, providing insight into molecular mechanisms-of-action as well as
revealing novel druggable sites for therapy design. These new advances provide ample opportunity for computational methods
(e.g., virtual screening, molecular dynamics simulations, and structure-based drug design) to catalyze the discovery of novel small
molecule therapeutics that can be easily translated from computer to bench and subsequently to the patient’s bedside. In this review,
we explore the utility of recent advances in biophysical methods coupled with well-established in silico techniques towards drug
development for diseases caused by dysfunctional ABC proteins.
1. Introduction
The adenosine triphosphate- (ATP-) binding cassette (ABC)
protein superfamily is comprised of transmembrane proteins
that utilize the energy generated from ATP binding and
hydrolysis to translocate physiological solutes or ions across
the lipid bilayers of certain cell types throughout the body [1].
Based on the directionality of transport, ABC transporters
can be classified as importers (bringing solutes into the cell)
or exporters (expelling solutes from the cell). Both importer
and exporter ABC proteins are present in bacteria and
archaea, whereas only exporters are found in eukaryotes [2–
4]. In humans, the importance of ABC transporters is high-
lighted by the fact that mutations in many members of the
superfamily have been associated with diseases [1, 5]. Impor-
tantly, many ABC proteins are also involved in the absorp-
tion, distribution, and excretion of xenobiotics, as they medi-
ate efflux of these biomolecules and their metabolites across
certain tissues [1, 6]. Further, several ABC proteins have
demonstrated importance inmediatingmultidrug resistance,
such that overexpression of these members in cancerous
tissues prevents accumulation of chemicals (i.e., chemother-
apeutics) via active transport, leading to subsequent relapse
and cancer progression [1, 7]. Taken together, it is clear that
ABC proteins have an important role in various physiological
processes and associated human diseases, whereas, in bacte-
ria and archaea, ABC importers/exporters are essential for
uptaking nutrients or effluxing toxic molecules, respectively,
across cell membranes.
The human ABC protein superfamily is comprised of 49
genes [5]. Most of these are efflux transporters; however cer-
tainmembers of the ABCprotein superfamily are unique. For
instance, the Cystic Fibrosis transmembrane conductance
regulator (CFTR/ABCC7) is a phospho-regulated chloride
channel, while the sulfonylurea receptors 1 and 2 (SUR1/
ABCC8 and SUR2/ABCC9, resp.) are regulators of inwardly
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Figure 1: Architecture of prototypic human and bacterial ABC proteins. Human (P-gp/ABCB1, CFTR/ABCC7), rat (SUR1/ABCC8), and
bacterial (Sav1866, MalEFGK
2
, BtuC
2
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F, and TM287/288) ABC proteins are shown relative to the plasma membrane [8–13]. P-gp is a
multidrug transporter, CFTR is a unique chloride channel, SUR1 is a regulator of an inwardly rectifying potassium channel, Sav1866 is an
exporter, MalEFGK
2
is a type I importer, BtuC
2
D
2
F is a type II importer, and TM287/288 is an exporter. MSDs are shown in green, NBDs
are in orange, extracellular domains (ECMs) are in blue, R-domain is in pink, and the phospholipid bilayer is in gray.The core structure of an
ABC protein consists of MSD1, NBD1, MSD2, and NBD2; however, SUR1/ABCC8 contains an additional MSD0. The full-length homology
model of human CFTR is shown [14].
rectifying potassium channels [15, 16]. Nonetheless, the core
structural architecture of ABC proteins is comprised of two
membrane-spanning domains (MSDs) and two nucleotide-
binding domains (NBDs), although certain “outlier” mem-
bers contain an additionalMSD (e.g.,MSD0ofMRP1/ABCC1
and SUR1/ABCC8) or regulatory domain (i.e., R-domain of
CFTR/ABCC7) (Figure 1) [17–20]. Based on the available
structural data, three types of ABC transporter families have
been characterized: (1) type I importers, (2) type II importers,
and (3) exporters. In the case of type I and II ABC importers,
certain members require a specific solute-binding protein
present in the periplasm, which is responsible for substrate
specificity and further coordinates the delivery of substrates
to the transporter [2, 4, 21]. Among these importers, the
best characterized ABC transporter system is the maltose
transporter, where several structural intermediates have been
captured by X-ray crystallography [8, 22, 23]. In comparison
to importers, the ABC exporters have long transmembrane
helices that extend into the cytoplasm as well as the so-
called “coupling-helix” that provides an interface with the
cytoplasmic NBDs [24]. This interface region seems to be a
hot-spot for structural stability, proper folding, and assembly
of different ABC transporters including CFTR (ABCC7) and
multidrug resistance proteins (MRPs) and furthermore a
location enriched in disease-causingmutations [6, 18, 25, 26].
ABC proteins responsible for multidrug resistance in
human cancers include the multidrug resistance protein 1
(MRP1/ABCC1), P-glycoprotein (P-gp/ABCB1), and the
breast cancer resistance protein (BCRP/ABCG2) [7, 27–29].
In specific tumour subtypes, these proteins are overexpressed
and prevent sufficient “cell killing” (i.e., apoptosis/necro-
sis) via chemotherapeutics. Thus, small molecule therapies
designed to inhibit these efflux pumps are of great interest to
the medical community as potential adjuvants to chemother-
apy. Accordingly, atomic resolution structures of these three
ABC proteins would be advantageous for medicinal chemists
as well as computational biologists, further guiding rational
in silico and subsequently in vitro, quantitative structure-
activity relationship (QSAR) studies and structure-based
drug design (SBDD) initiatives [30, 31].
Design of small molecule modulators for other disease-
relevant ABC protein targets (e.g., CFTR/ABCC7, TAP1/
ABCB2, and TAP2/ABCB3; Table 1) could also be facilitated
once biophysicalmethodologies enablemore efficient charac-
terization of these polytopic and highly dynamic membrane
proteins. To date, approximately 670 membrane protein
structures have been deposited in the Protein Data Bank
[32]. However, most of these are from non-human species,
including other mammals (mainly rodents), archaea, bacte-
ria, fungi, parasites, and plants. Thus, in silico generation of
homology models is typically necessary to capture the struc-
tural specificities of human membrane proteins, and this
is not different for the ABC superfamily. In addition, it is
important to note that of these∼670membrane protein struc-
tures (among a database of approximately 125,000 structures)
only 37 of these are ABC proteins (∼0.5% of membrane
proteins or ∼0.03% of all structurally characterized proteins),
and most have been deposited in recent years; further, only
five full-length human ABC proteins have been structurally
characterized to date [32, 33]. Therefore, although these pro-
teins are therapeutically relevant, they are indeed structurally
underrepresented. By overcoming challenges associated with
the complexities of their structural arrangement and dynam-
ics in biological systems, high resolution structures of ABC
proteins associated with human diseases will become more
readily available. This would provide sufficient insight into
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Table 1: Relative characterization of ABC proteins that cause human diseases when mutated.
Gene Protein Endogenous
substrate(s) Disease
Publications on
disease
Structure(s) in
Protein Data Bank
Ref.
ABCA1 — Cholesterol,
phospholipids Tangier disease >700 N
[1]
ABCA3 — Lipids, cholesterol Newborn respiratorydistress syndrome >16,000 N
[42]
ABCA4 — Vitamin A derivatives Stargardt disease >500 N [1]
ABCA12 — Lipids Harlequin-typeichthyosis >1,000 N
[43]
ABCB2 TAP1 Cytosolic peptides Ankylosing spondylitis >16,000 Y (cryo-EM, X-ray) [40, 44, 45]
ABCB3 TAP2 Cytosolic peptides Ankylosing spondylitis >16,000 Y (cryo-EM) [40, 45]
ABCB4 MDR2 Phospholipids
Progressive familial
intrahepatic cholestasis
type 3
>100 N [1]
ABCB7 — Heme, iron-sulfur
clusters
X-linked sideroblastosis
and anemia >30 N
[1]
ABCB11 BSEP Taurocholate, cholate
conjugates
Progressive familial
intrahepatic cholestasis
type 2
>100 N [1]
ABCC2 MRP2 Organic anions Dubin-Johnsonsyndrome >800 N
[46]
ABCC6 MRP6 Organic anions Pseudoxanthomaelasticum >1,700 N
[47]
ABCC7 CFTR Chloride, bicarbonate Cystic Fibrosis >45,000 Y (cryo-EM, X-ray,NMR)
[15, 41, 48, 49]
ABCC8 SUR1 Sulfonylurea
Familial persistent
hyperinsulinemic
hypoglycemia of infancy
>100 Y (cryo-EM) [1, 9]
ABCC9 SUR2 Sulfonylurea
Dilated cardiomyopathy
with ventricular
tachycardia
>100 N [1]
ABCD1 ALD Fatty acids Adrenoleukodystrophy >2,000 N [1]
ABCG5 — Sterols Sitosterolemia >200 Y (X-ray) [50, 51]
ABCG8 — Sterols Sitosterolemia >200 Y (X-ray) [50, 51]
their structure-function relationships, as well as identify
novel druggable pockets to aid in the in silico design of
pharmacological chaperones, and/or initiation of virtual
screening campaigns, in order to repair mutant ABC proteins
towards the wild-type conformation.
To date, certain biophysical methods have been pref-
erentially used to characterize the currently available ABC
proteins, and these include X-ray crystallography, cryo-
electron microscopy (cryo-EM), and nuclear magnetic res-
onance (NMR) spectroscopy. Each technique has its own set
of advantages and disadvantages, and these will be explored
in more detail in Table 2. In brief, X-ray crystallography has
been the primary technique of choice, as it was used to resolve
the first protein structure (i.e., myoglobin in 1960; [34]) and
has subsequently been extensively used for soluble proteins,
as well as some membrane proteins. On the other hand,
NMR spectroscopy, in practice since the early 1980s, has been
mainly utilized to understand protein dynamics and folding,
including that of certain membrane proteins [35]. How-
ever, the relatively “new” (late 1980s) method, cryo-EM, is
becoming more popular and powerful, especially due to the
recent improvements in electron detectors and accompany-
ing three-dimensional protein reconstruction software [36–
38]. Importantly, unlike X-ray crystallography, cryo-EMdoes
not require proteins to form crystal lattices and thus can be
used to investigate asymmetric nature and distinct conforma-
tional spectrum of proteins such as those in the ABC super-
family [19, 39]. Accordingly, additional innovations to the
cryo-EM workflow have allowed for higher resolution struc-
tures of increasingly complex protein samples (e.g., bearing
posttranslational modifications, ligands, and macromolecu-
lar binding partners) to be achieved, including those of sev-
eral disease-relevant and plasma membrane-associated ABC
proteins in recent years [40, 41]. Appropriately, today’s struc-
tural biology pursuits have been aptly named a “cryo-EM
revolution” for drug discovery [36–38].
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Table 2: Comparison of commonly used biophysical techniques.
Parameter Biophysical technique
X-ray crystallography NMR spectroscopy Cryo-EM
MW range of proteins 2–3,000 kDa
60–65 kDa for all-atom;
800–1,000 kDa with sparse
labeling
2–3,000 kDa
Time required Up to several years Up to 1 year A few months
Typical resolution range 2–4 A˚ N/A >4 A˚
Membrane proteins Y Y Y
Protein dynamics N Y N
Recapitulates physiology N Y/N Y
Artifacts Crystallization artifacts,single conformation
Reflecting conformational
averaging
Possible sample preparation
artifacts
Expertise required Y Y Y
Major advantage Streamlined, highresolution information
Providing information on
protein dynamics
Fully functional
macromolecular complexes
Major disadvantage Requiring stable proteincrystal that diffracts well
Requiring high
concentration sample
Low signal-to-noise ratio
for proteins smaller than
300 kDa
2. In Silico Methods Facilitate Drug Discovery
for Disease-Associated ABC Proteins
Using solved structures of disease-associated ABC proteins,
many of the traditional in silico structure-based tools can be
used to facilitate drug development (Figure 2). In general, for
diseases caused by missense mutations to certain members
of the ABC superfamily, the first step towards drug discov-
ery and rational drug design is to model these side-chain
variants onto the tertiary protein structure and subsequently
conduct molecular dynamics (MD) simulations to “relax”
the biomolecular system so that it reaches its lowest energy
conformation within the biological constraints of a phospho-
lipid bilayer environment [14, 52, 53]. With these energy-
minimized mutant ABC protein structures, disease-relevant
conformations are sampled, potentially enabling the identi-
fication of aberrant structural motifs as well as druggable
pockets and further allowing for therapeutically relevant
target-specificity with respect to the development of small
molecule modulators.
However, as previously mentioned, most ABC proteins
that have been structurally characterized and reported in the
Protein Data Bank to date are from non-human species [32].
Thus, homology modeling is typically required at the onset
of ABC-centric drug development initiatives. Many of the
human models generated and published during the previous
decade were based on X-ray crystal structures of homolo-
gous bacterial templates (e.g., Sav1866 and MsbA; [11, 54]),
and these models have provided sufficient utility for drug
development via in silico medicinal chemistry and vir-
tual screening approaches, especially for Cystic Fibrosis
(i.e., using CFTR/ABCC7 models; [55–58]). However, even
though compounds identified in these in silico studies have
had positive effects in vitro, to date, none have been translated
to the clinic; therefore, caution must be taken when using
modeled human structures to guide drug discovery efforts.
Accordingly, the direct structural characterization of human
ABC proteins is desired, as it would mitigate risks associated
with using bacterial structure-based homology models (i.e.,
low sequence identity, structural diversity). Importantly, in
certain aspects, cryo-EM has superseded the usefulness of
X-ray crystallography and NMR spectroscopy in the ABC
protein field over the past decade, since it has been recently,
successfully, and frequently employed to resolve the complex,
polytopic, and usually asymmetric nature of this protein
superfamily (even human structures) at higher resolutions
(and near full-length polypeptides) than previously possible
[40, 41].
By using these high-quality, human disease-relevant bio-
physical structures, best-in-class therapies can be developed.
Appropriate medicinal chemistry approaches facilitated by
well-established in silico techniques, including homology
modeling [59],MDsimulations [60, 61], virtual screening [62,
63], QSAR [64, 65], and SBDD [66], can and have been used
to drive therapeutic discovery for ABCproteins,mainly those
requiring functional inactivation (i.e., ABCC1, ABCB1, and
ABCG2 as previously mentioned). For example, inhibitors of
ABCB1 have been identified using a combination of in silico
techniques, and these small molecules are currently being
evaluated in vitro as well as in vivo for inhibition of tumori-
genesis [67, 68].
Another computational tool, which has provided much
insight into the conformational dynamics, ATP-dependent
transport/gating cycles, and putativemechanism-of-action of
small molecule modulators of certain ABC proteins, is that of
MD simulations [61]. This methodology considers both the
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Figure 2: Experimental workflow from biophysical characterization of ABC proteins in multiple conformational states to in silico discovery and
design of small molecule modulators. Biophysical techniques are shown in green boxes (a), multiple conformations of a representative ABC
protein are shown in the blue box (b), and in silico methods are shown in orange boxes (c). The cryo-EM image is modified from [39].
biophysics and biochemistry of ABC proteins embedded in
its native phospholipid bilayer environment, providing phy-
siologically-relevant information about conformational dyn-
amics as well as potential druggability.Thus, MD simulations
can be used to sample conformational states which may be
difficult to be structurally characterized using current bio-
physical methods, providing actionable information into the
putative druggability of specific functional transition states.
In addition, virtual screening is a complementary in silico
tool which has been successfully used to identify and evaluate
lead, drug-like small molecule candidates for several ABC
proteins, mainly ABCB1 [62, 63]. Accordingly, chemical
libraries of thousands to millions of compounds can be effi-
ciently and computationally screened against an ABC protein
target of interest with minimal upfront requirements of cost
and time.This approach is typically used to narrow the chem-
ical space of possible modulators to those with promising
scaffolds. Furthermore, using this approach, lead candidates
6 International Journal of Medicinal Chemistry
are ranked in terms of scaffold suitability and complemen-
tarity to the target of interest, and subsequently, represen-
tative chemicals are chosen for in vitro validation studies.
Additional approaches which have demonstrated usefulness
in solving the drug design problem involve QSAR and SBDD.
QSARaims to identify bioactivemodulators by evaluating the
predicted functional activity of a spectrumof drug derivatives
[64, 65], while SBDD uses scaffolds of known modulators
to precisely reposition/modify chemical moieties in order to
improve predicted binding affinity and thus putative drug
efficacy [66]. Importantly, these in silico approaches have
been frequently used to the develop small molecule mod-
ulators of ABC transporters, mainly ABCB1, with several
examples of success [64–66].
Lastly, any small molecules identified using these afore-
mentioned in silico approaches must abide by previously
established (and predictive) drug development algorithms,
including Lipinski’s “Rule of 5” [69] and the “Golden Tri-
angle” [70]. Both parameters focus on the physicochemical
properties of small molecules, mainly molecular weight,
hydrophobicity (i.e., partition and distribution coefficients,
logP, and logD, resp.), and calculated hydrogen-bond accep-
tors and donors. Lipinski’s rules evaluate drug plausibility in
terms of oral bioavailability in humans and consider a drug’s
pharmacokinetics (i.e., absorption, distribution, metabolism,
and excretion), while the Golden Triangle aims to compu-
tationally optimize oral absorption/permeability as well as
drug clearance. These algorithms classify compounds based
on molecular weight and logD, in order to evaluate drug-
likeness, efficacy, potency, clearance, and permeability, and
any in silico-based discovery of a putative ABC protein
modulator must meet these criteria in order to have potential
therapeutic value in the clinic [71].
3. Therapy Development for Multidrug
Resistance in Cancer, Cystic Fibrosis, and
Herpes Simplex Virus Infection
As previously described, ABC proteins are found in all three
domains of life (bacteria, archaea, and eukarya), playing
many key physiological roles required for normal biology.
ABCB1 is no exception; however, when this ABC transporter
is overexpressed it is disease-causing in humans. ABCB1
was the first ABC protein to be identified and cloned, as it
was highly expressed in the tumours of cancer patients [72].
ABCB1 is a polyspecific drug efflux pump, required for
transport of physiological substrates and xenobiotics across
certain tissues of the body, yet in cancer, this protein employs
a survival response and becomes overexpressed in order to
efflux chemotherapeutics [1, 7]. Thus, ABCB1 is an impor-
tant target for adjuvant cancer therapy, such that specific
inhibitors could potentially increase intracellular concentra-
tions of cotreated chemotherapies; third generation ABCB1
inhibitors, developed in part using the biophysical structure
of ABCB1 as a template for small molecule discovery, have
shown efficacy towards tumorigenesis [7, 10].
Another ABC protein, CFTR (ABCC7), is the most
unique member of the ABC superfamily. Cloning of the
CFTR gene in conjunction with the discovery of CFTR as
a phospho-regulated chloride channel was seminal in the
development of high-throughput, target-based initiatives for
Cystic Fibrosis drug discovery [15, 73–75]. Remarkably, these
efforts lead to the development of twomutation-specific small
molecule therapies for Cystic Fibrosis, a prototypic feat that
would be much welcomed for other disease-associated ABC
proteins [76]. Although the structure-based homology mod-
els of CFTRwere important in classifying various experimen-
tal drugs based on their site of action on the tertiary struc-
ture of CFTR, a molecular understanding of drug synergy
(achieved by one of the FDA-approved therapies: Orkambi)
could not be achieved using in silico tools alone [76, 77]. Fur-
thermore, with the advent of recent innovations and improve-
ments to cryo-EM-based techniques, the structure of CFTR
was recently solved, paving the way for subsequent structure-
based drug development of the next generation of more
effective Cystic Fibrosis therapies [40].
In addition, the transporter associated with antigen pro-
cessing (TAP1/ABCB2) is an important ABC family member
required for adaptive immunity [78]. TAP1 transports foreign
peptide antigens from invading pathogens into the endoplas-
mic reticulum of immune cells and allows these peptides to
become displayed by the major histocompatibility complex
on the cell surface following anterograde trafficking [78].
Transport to the plasmamembrane allows recognition of for-
eign antigen by CD8+ T-cells via a macromolecular complex.
This is relevant, as the herpes simplex virus is a unique
pathogen which evades this immune response by expressing
a peptide-based inhibitor of TAP1. Again, with the advent
of recent innovations and improvements to cryo-EM-based
techniques, the binding site of this inhibitor peptide was
recently discovered and mechanism-of-action elucidated,
further allowing for possible SBDD of small molecule modu-
lators of the herpes simplex virus [40].
Finally, as more ABC proteins become structurally char-
acterized in multiple conformations using state-of-the-art
biophysical techniques, our understanding of similarities
(and differences) between each unique familymemberwill be
further elucidated. This may facilitate identification of drug-
gable binding sites which are only present in the mutant form
of each target of interest, thereby allowing for efficient in silico
virtual screening and SBDD initiatives aimed at developing
ABC- andmutation-specific therapeutics.This approachmay
also assist with the repurposing of drugs within the ABC
superfamily. One recent example is the repurposing of the
CFTR/ABCC7-specific potentiator, ivacaftor (Kalydeco), for
patients with mutations in a homologous ABC protein:
ABCB4 [79]. Both in silico and in vitro methods were syn-
ergistically used to validate this hypothesis, and furthermore,
this finding highlights the importance of accurate structure-
based classification of proteins and homologous familymem-
bers with respect to translational drug discovery.
4. Conclusion
ABC proteins are required for normal physiology and can
cause disease when mutated. Biophysical techniques aim to
structurally characterize this family of membrane proteins,
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and recent improvements to certain techniques, mainly cryo-
EM, have elucidated the tertiary topology of several disease-
relevant ABC proteins. This structural information provides
a foundation for in silico-based drug discovery and drug
development initiatives (e.g., virtual screening and QSAR)
intended to repair misfolded and/or dysfunctional mutant
ABC variants.Thus, potentially druggable sites can be identi-
fied and investigatedwith respect to the compatibility of small
molecule therapeutics aimed at improving structural defects
caused by variousmutations, and further, specificmodulators
can be designed using various well-established in silico
approaches. Taken together, the advent of high resolution
structures of these human disease-relevant proteins provided
ample opportunity to translate findings from the lab into the
clinic.
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